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Abstract
Background: In order to reduce fatal self-poisoning legislation was introduced in the UK in 1998 to restrict pack
sizes of paracetamol sold in pharmacies (maximum 32 tablets) and non-pharmacy outlets (maximum 16 tablets),
and in Ireland in 2001, but with smaller maximum pack sizes (24 and 12 tablets). Our aim was to determine
whether this resulted in smaller overdoses of paracetamol in Ireland compared with the UK.
Methods: We used data on general hospital presentations for non-fatal self-harm for 2002 - 2007 from the
Multicentre Study of Self-harm in England (six hospitals), and from the National Registry of Deliberate Self-harm in
Ireland. We compared sizes of overdoses of paracetamol in the two settings.
Results: There were clear peaks in numbers of non-fatal overdoses, associated with maximum pack sizes of
paracetamol in pharmacy and non-pharmacy outlets in both England and Ireland. Significantly more pack
equivalents (based on maximum non-pharmacy pack sizes) were used in overdoses in Ireland (mean 2.63, 95% CI
2.57-2.69) compared with England (2.07, 95% CI 2.03-2.10). The overall size of overdoses did not differ significantly
between England (median 22, interquartile range (IQR) 15-32) and Ireland (median 24, IQR 12-36).
Conclusions: The difference in paracetamol pack size legislation between England and Ireland does not appear to
have resulted in a major difference in sizes of overdoses. This is because more pack equivalents are taken in
overdoses in Ireland, possibly reflecting differing enforcement of sales advice. Differences in access to clinical
services may also be relevant.
Background
Paracetamol is commonly used in intentional self-poi-
soning [1]. Overdoses of paracetamol may result in liver
damage, which can be fatal. As a result of a large num-
ber of deaths and liver transplants each year due to
hepatotoxicity resulting from paracetamol overdose in
the UK [2-4], legislation came into force in September
1998 to restrict pack sizes of paracetamol (and aspirin
and their compounds) sold over the counter to a maxi-
mum of 32 tablets in pharmacies and 16 in non-phar-
macy outlets [5]. Labelling and other packaging changes
occurred around the same time.
In Ireland, similar legislation was introduced in Octo-
ber 2001 [6] but pack sizes were restricted to consider-
ably lower maximum amounts than in the UK, namely a
maximum pack size of 24 tablets in pharmacies and 12
tablets in non-pharmacy outlets, with just a single pack
to be supplied in any one transaction.
The UK legislation appears to have had beneficial effects,
at least in England and Wales, in terms of reduced sizes of
overdoses and numbers of deaths and liver transplantations
[1,7], although some commentators have disputed this
[8-10]. These effects were not seen in Scotland [11]. In Ire-
land, on the basis of calls to the National Poisons Centre,
the change in pack sizes of paracetamol appeared to have
resulted in smaller overdoses (i.e. reduced number of tablets)
in the first two years after the legislation [12]. Data on deaths
involving paracetamol in Ireland have not been published.
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of deaths due to paracetamol-induced hepatoxicity [1],
the death toll remains high. The annual number of poi-
soning deaths involving paracetamol alone which
received a verdict of suicide, undetermined or accidental
death registered during 2000 - 2008 varied between 90
and 155. In addition there are considerable numbers of
deaths involving paracetamol compounds and paraceta-
mol taken with other drugs [13-15].
Some authors have suggested that the maximum pack
size for pharmacy sales in the UK should have been set
at a lower level, more akin to the maximum pack size in
Ireland [1,16]. Support for this comes from toxicological
studies in which ingestion of 15 grams of paracetamol
(i.e. 30 tablets) appeared to be associated with consider-
ably elevated risk of hepatotoxicity [17]. A smaller maxi-
mum pack size might therefore have introduced a safety
margin.
In order to provide information relevant to the ques-
tion of whether it might be beneficial to further reduce
pack sizes of paracetamol in the UK, we have conducted
an investigation in which we have compared sizes of
overdoses of paracetamol taken in the UK and in Ire-
land. We have used data from the Multicentre Monitor-
ing of Self-harm project in England [18,19] and the
National Deliberate Self-harm Registry in Ireland [20].
Methods
We investigated the number of tablets of paracetamol
consumed in overdoses which resulted in presentation
between 2002 and 2007 to six general hospitals in three
centres in England, and all general hospitals in Ireland,
for persons aged 10 years or more. Data were restricted
to non-fatal intentional self-poisoning episodes in which
paracetamol was the sole medicinal agent consumed
(with or without co-ingestion of alcohol), and where at
least four tablets were taken at one time (i.e. double the
maximum recommended single therapeutic dose of two
tablets).
Data sources
Multicentre Monitoring of Self-harm in England Project
This project is based on monitoring of general hospital
presentations for intentional self-poisoning and self-
injury in six major general hospitals in England [18,19],
one in Oxford, three in Manchester and two in Derby.
The study is coordinated by the Centre for Suicide
Research at Oxford University. Information is collected
on all presentations for intentional self-poisoning to the
general hospitals, and includes (among other factors)
gender, age, drugs used for self-poisoning, numbers of
tablets, and consumption of alcohol during the six
hours prior to self-poisoning and as part of the over-
dose. The information about numbers of tablets taken
in overdose is usually based on patient self-report, but
often corroborated by accounts of relatives and other
informants and inspection of medicine containers.
National Registry of Deliberate Self Harm in Ireland
Information is collected on all presentations for inten-
tional self-poisoning and self-injury to general hospitals
in Ireland [20]. Information used in this study is col-
lected on the same items as in the Multicentre Study of
Self-harm in England, exceptt h a ta l c o h o lc o n s u m p t i o n
related to self-poisoning is just recorded as a single vari-
able (alcohol involved at the time of overdose).
Ethical Approval
The monitoring systems in Oxford and Derby have
approval from local Health/Psychiatric Research Ethics
Committees to collect data on self-harm for local and
multicentre projects. Self-harm monitoring in Manche-
ster is part of a clinical audit system, and has been rati-
fied by the local Research Ethics Committee. All three
monitoring systems are fully compliant with the Data
Protection Act of 1998. All centres have approval under
Section 251 of the NHS Act 2006 (formerly Section 60,
Health and Social Care Act 2001) to collect patient
identifiable information without patient consent. The
National Registry of Deliberate Self Harm in Ireland has
ethical approval from the National Research Ethics
Committee of the Faculty of Public Health Medicine,
a n df r o mt h er e l e v a n th o s p itals and Health Service
Executive ethics committees.
Data Analysis
Analyses comparing the number of tablets consumed,
and number of packs used in overdoses of paracetamol
in England and Ireland were conducted using the Chi-
square, Mann-Whitney U and Kruskal Wallis tests. Ana-
lyses were done on combined data, and separately by
gender, age group and alcohol involvement with the
overdose (data from the English study on alcohol con-
sumed during the six hours before self-poisoning and/or
as part of the overdoses were combined for this
analysis).
The number of packs used was calculated as a multi-
ple of the non-pharmacy maximum pack size in each
country, from 1 pack to 9 or more packs (e.g. in Eng-
land an overdose involving up to 1 pack was 4-16
tablets; 2 packs was 17-32 tablets; 3 packs was 33-48
tablets, and so on. In Ireland, up to 1 pack was 4-12
tablets; 2 packs 13-24 tablets, 3 packs 25-36 tablets, and
so on).
Results
Study samples
During the six-year study period 2002 to 2007 there
were 31,107 hospital presentations for self-poisoning
Hawton et al. BMC Public Health 2011, 11:460
http://www.biomedcentral.com/1471-2458/11/460
Page 2 of 7(alone) in the three English centres (six hospitals) and
42,877 (40 hospitals - 34 in 2002, 37 in 2003, 38 in
2004-2005, and 40 in 2006-2007) in Ireland. Of these,
paracetamol was involved in 10,208 (32.8%) episodes in
the English centres and 9057 (21.1%) in Ireland. Parace-
tamol alone (with or without alcohol) was involved in
5444 episodes in the English centres and in 3886 in
Ireland.
Data on number of tablets taken in overdose was
missing for 559 (10.3%) episodes in the English centres
and 358 (9.2%) in Ireland. We also excluded episodes
where fewer than 4 tablets were taken, where gender
was missing, and where age was missing, or patients
were under 10 years (totalling 27 (0.5%) in the English
centres and l9 (0.5%) in Ireland). Thus the samples for
inclusion in the study consisted of 4858 episodes in the
English centres and 3509 in Ireland.
The female: male gender ratio for episodes was some-
what larger in the Irish patients (2.1:1) than in England
(1.8:1) (Table 1). The age distributions of the two sam-
ples showed greater proportions of younger individuals
in the Irish patients and older people in the English
patients. Alcohol use at the time of overdose occurred
with similar frequency in the English and Irish patients.
Number of tablets taken in overdoses
The pattern of the numbers of tablets taken in over-
doses in the English centres and in Ireland is shown in
Figure 1. There were clear peaks in each of the coun-
tries corresponding to the pack size limits for non-phar-
macy and pharmacy sales. Thus in the English sample
there were peaks at 16 and 32 tablets and in the Irish
sample at 12 and 24 tablets. There were also peaks at
multiples of these pack sizes. There were, in addition,
peaks in both samples at 10 and multiples of 10 tablets.
The median number of tablets consumed in paraceta-
mol overdoses did not differ significantly between the
English (median 22 tablets) and Irish (median 24 tablets)
patients (Table 2).
In both countries the number of tablets taken differed
significantly by gender, with larger overdoses in males
than females (England, Kruskall Wallis Z = 150.882, P <
0.001; Ireland, Z = 71.052, P < 0.001). There was also a
difference by age group, with larger overdoses being
taken by older people in both males (England, Z =
48.948, P < 0.001; Ireland, Z = 36.555, P < 0.001) and
females (England, Z = 68.973, P < 0.001; Ireland, Z =
22.165, P < 0.001).
When the samples were divided into three age groups
and the two countries compared a small but neverthe-
less statistically significant difference in the median
number of paracetamol tablets consumed between the
Table 1 Episodes of self-poisoning with known number
of paracetamol tablets in England and Ireland 2002-2007
England
N = 4858
Ireland
N = 3509
Chi sq P
Gender
Male 1736 (35.7%) 1146 (32.7%)
Female 3122 (64.3%) 2363 (67.3%) 8.537 0.003
Age group
10-24 y 2186 (45.0%) 1682 (47.9%)
25-34 y 962 (19.8%) 753 (21.5%)
35+ y 1710 (35.2%) 1074 (30.6%) 19.442 <0.001
Alcohol use
Yes 1851 (38.1%) 1259 (35.9%)
No or not known 3007 (61.9%) 2250 (64.1%) 4.311 0.038
Episodes of self-poisoning with known number of paracetamol tablets for
persons aged 10 years or more in three centres (six general hospitals) in
England, and in Ireland, 2002 to 2007
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Figure 1 Distribution of tablets taken in paracetamol overdose in England and Ireland. Distribution of tablets taken in paracetamol
overdose by persons aged 10 years or more, in England (three centres; six general hospitals) (N = 4858), and in Ireland (N = 3509), 2002 to
2007, shown as percentage of total number of overdoses of paracetamol in each country.
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Page 3 of 7English (median 24) and Irish (median 23) samples was
found in age group 35 years and over (Table 2). This
difference was confined to females.
Involvement of alcohol in overdoses
In both England and Ireland, when alcohol was known
to be involved in overdoses more paracetamol tablets
tended to be taken (England, Z = -3.141, P = 0.002; and
Ireland, Z = -2.105, P = 0.035). This pattern was found
in males, but not females, in both countries (Table 3).
There was a non-significant trend for smaller overdoses
in males in Ireland who had not consumed alcohol
compared with those in England.
Number of packs used in overdoses
When the numbers of tablets consumed in overdoses by
individuals in each country were categorised into num-
ber of pack equivalents used (based on the non-phar-
macy maximum pack size in each country, i.e. 16 tablets
in England and 12 in Ireland), the mean number of
packs used was greater in Ireland (2.63, 95% CI = 2.57-
2.69) than England (2.07, 95% CI 2.03-2.10). The largest
proportion of overdoses involved one pack only in Eng-
land (39.0%), and three or more packs in Ireland (37.9%)
(Table 4). Females and the younger age group (15-24
years) were more likely to use one pack in England and
two packs in Ireland. Males and individuals in older age
groups (25-34, 35+ years) were far more likely to use
three or more packs in Ireland than in England.
Discussion
We have used data collected through special registers in
six general hospitals in three centres in England and in
all general hospitals in Ireland to determine whether the
differences in pack sizes of paracetamol sold over the
counter in pharmacies and non-pharmacy outlets in the
UK and Ireland are reflected in the size of overdoses of
paracetamol. There were peaks in the numbers of tablets
taken in paracetamol overdoses for both England and
Ireland which reflected the maximum pack sizes in the
respective countries. These were not only found for the
maximum single pack sizes, but also for multiples of
these pack sizes. The latter could reflect overdoses
where multiple packs were purchased for the acts. The
additional peaks in both samples at 10 and multiples of
10 tablets presumably reflect effects of rounding or
approximation by patients, and, possibly, clinicians.
There was a marked difference between England and
Ireland in terms of the pack equivalents of paracetamol
taken in overdoses, based upon the maximum pack size
for non-pharmacy and pharmacy preparations in the
two countries. More packs were in general consumed in
overdoses in Ireland. This difference was found for both
genders and across all three age groups that were exam-
ined. This raises the following questions: (a) Is advice
on sales of packs being followed to the same extent in
Table 2 Paracetamol tablets taken in overdose in
England and Ireland 2002-2007 by gender and age
group
England
N = 4858
Ireland
N = 3509
Mann
Whitney
median (IQR)
1 median (IQR)
1 ZP
Both
genders
22 (15-32) 24 (12-36) -0.758 0.449
Males 28 (16-40) 27 (18-48) -2.015 0.044
Females 20 (13-32) 20 (12-30) -1.651 0.099
10-24 y 19 (12-32) 20 (12-30) -1.179 0.239
25-34 y 24 (16-40) 24 (15-45) -1.509 0.131
35+ y 26 (16-40) 24 (12-40) -2.862 0.004
Males
10-24 y 22 (15-32) 24 (14-36) -1.364 0.173
25-34 y 30 (16-45) 30 (20-50) -2.128 0.033
35+ y 30 (16-48) 30 (20-49) -1.083 0.279
Females
10-24 y 16 (12-30) 20 (12-28) -0.655 0.513
25-34 y 20 (14-32) 24 (12-36) -0.543 0.587
35+ y 24 (16-32) 23 (12-32) -3.843 <0.001
1 IQR = interquartile range
Number of tablets of pure paracetamol taken alone in overdose in England
(three centres, six general hospitals), and in Ireland, 2002 to 2007, by gender
and age group
Table 3 Number of paracetamol tablets taken in
overdose in England and Ireland 2002-2007 by alcohol
use
England N =
4858
Ireland N =
3509
Mann
Whitney
median (IQR)
1 median (IQR)
1 ZP
Both genders
Alcohol 24 (16-35) 24 (13-36) -0.619 0.536
No/Not
known
20 (14-32) 24 (12-36) -0.328 0.743
Males
Alcohol 30 (16-40) 30 (18-48) -1.086 0.277
No/Not
known
28 (16-40) 25.5 (16-48) -1.739 0.082
Females
Alcohol 20 (14-32) 20 (12-30) -1.496 0.135
No/Not
known
20 (13-32) 20 (12-30) -0.954 0.340
1 IQR = interquartile range
Number of tablets of pure paracetamol taken alone in overdose in England
(three centres; six general hospitals), and in Ireland, 2002 to 2007, by alcohol
use at the time or prior to the overdose
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Page 4 of 7the two countries? (b) Do purchasing patterns differ,
with perhaps paracetamol packs being bought with
greater frequency in Ireland, so that more are available
in households? (c) Are there differences in patient char-
acteristics between the two countries influencing pat-
terns of self-poisoning? and (d) Are individuals in
Ireland who have taken paracetamol overdoses less likely
to present to hospital when the amount taken is rela-
tively small? Unfortunately, we do not have access to
over-the-counter sales data for the two countries. We
have no reason to believe that there are major differ-
ences between the characteristics of patients who take
paracetamol overdoses in England and Ireland, except
that it appears that paracetamol is taken more fre-
quently in overdose in England, the female to male gen-
der ratio is greater in Ireland, and a somewhat greater
proportion of patients in Ireland are in the youngest age
group. These differences do not, however, appear large
enough to explain the extent of the difference in pat-
terns of pack consumption in overdoses. We do not
h a v ei n f o r m a t i o ni nt h i ss t u d yo nt h ef r e q u e n c yo f
hospital presentations in relation to size of overdoses in
the two countries. In a recent schools-based study the
frequency with which adolescents who reported taking
overdoses (often of paracetamol) presented to hospital
did not differ markedly between England and Ireland
[21-23]. However, one important difference between the
two countries is that many individuals who present to
emergency departments in Ireland are subject to a fee,
whereas this is not the case in England. Also, obtaining
general practitioner care in Ireland often involves a fee,
which could influence willingness to seek help for emo-
tional problems and therefore risk of self-poisoning. The
more rural nature of Ireland, and hence larger distances
to hospitals for many residents, could also influence pre-
sentation to emergency departments.
An important possible explanation for the difference
in number of packs used for overdoses in England and
Ireland may be less rigorous enforcement of sales advice
contained in Regulatory notices in Ireland compared
with England. A study conducted before the Irish legis-
lation was introduced indicated that sales advice for
non-pharmacy outlets from the Irish Medicines Board
was often not being followed [24]. Following the intro-
duction of the legislation, researchers visiting pharmacy
and non-pharmacy outlets in Dublin were able to pur-
chase in excess of statutory limits of paracetamol in a
single transaction in half of all pharmacies and the
majority of non-pharmacy outlets. This situation largely
persisted when the researchers revisited outlets a year
later [25]. The present situation in Ireland in this regard
requires investigation. There is also evidence of breach-
ing of the legislation in non-pharmacy outlets in Eng-
land [26] but this appeared to be to a far lesser degree
than in the post-legislation study in Ireland [25].
There was only limited evidence that different restric-
tions in pack sizes in England and Ireland may have had
an impact on sizes of overdoses taken in the two coun-
tries. While there was no difference when all episodes
were considered, smaller paracetamol overdoses were
taken in Ireland than England by females aged 35 years
and over. Although the difference was small, a relatively
minor shift in number of tablets taken in overdoses
could have a considerable effect at a population level in
terms of numbers of patients developing hepatotoxicity.
Whether or not alcohol was involved in the act of self-
poisoning made little difference to the result, except for
a trend for smaller overdoses to be taken by males in
Ireland who did not consume alcohol in association
with the act.
Strengths and limitations
The study involved large numbers of patients in both
countries. The Irish sample was based on all overdose
presentations to general hospitals in Ireland. However,
Table 4 Number of paracetamol pack equivalents used in
overdose in England and Ireland 2002-2007
England Ireland Chi square P
N (%) N (%)
Both genders
1 pack 1893 (39.0) 949 (27.0)
2 packs 1790 (36.8) 1229 (35.0)
3+ packs 1175 (24.2) 1331 (37.9) 215.6 <0.001
Males
1 pack 521 (30.0) 217 (18.9)
2 packs 638 (36.8) 327 (28.5)
3+ packs 577 (33.2) 602 (52.5) 109.8 <0.001
Females
1 pack 1372 (43.9) 732 (31.0)
2 packs 1152 (36.9) 902 (38.2)
3+ packs 598 (19.2) 729 (30.9) 135.6 <0.001
Age 15-24
1 pack 1019 (46.6) 495 (29.4)
2 packs 768 (35.1) 657 (39.1)
3+ packs 399 (18.3) 530 (31.5) 145.3 <0.001
Age 25-34
1 pack 324 (33.7) 160 (21.2)
2 packs 354 (36.8) 244 (32.4)
3+ packs 284 (29.5) 349 (46.3) 57.9 <0.001
Age 35+
1 pack 550 (32.2) 294 (27.4)
2 packs 668 (39.1) 328 (30.5)
3+ packs 492 (28.8) 452 (42.1) 52.9 <0.001
Number of non-pharmacy pack equivalents of pure paracetamol used in
overdoses in England (three centres, six general hospitals) (maximum pack
size = 16 tablets), and in Ireland (maximum pack size = 12 tablets), 2002 to
2007.
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general hospitals in three centres. It is not known if
these are representative of all general hospitals in Eng-
land, particularly since some of them are in large urban
areas and rates of self-harm vary across the centres
[18,19]. The overall rates and patterns of self-harm in
Ireland and England appear to be similar [18,20,27].
We chose a relatively low amount for defining self-
poisoning as some people who intentionally take an
overdose only consume a few tablets, even some with
suicidal intent [28].
The recording of the number of tablets taken in over-
doses relied largely on patient self-report, which is known
to be subject to inaccuracy [29]. Also, there was evidence
of possible rounding or approximation, with peaks in the
numbers of tablets reportedly taken in overdoses in both
countries at 10 and multiples of 10 tablets. The peaks seen
at numbers of tablets equivalent to the different pack sizes
in the UK and Ireland may more accurately reflect sizes of
overdose as patients may be more likely to consume whole
packets of tablets, especially when these have been pur-
chased for the purpose of self-poisoning.
A further limitation is that we did not have data on
suicidal intent [30] for patients from the two countries.
Suicidal intent can influence the danger of acts of self-
harm [31]. Data on suicidal intent for patients in the
two countries could therefore have helped in the inter-
pretation of the findings.
We have restricted our study to pure paracetamol over-
doses, with or without co-ingestion of alcohol. We do not
know whether the findings would also apply to overdoses
of paracetamol compounds which are subject to the same
pack size limitations, or those where paracetamol or
paracetamol compounds are taken with other substances.
Finally, we do not have data for Ireland on possible
changes in size of overdoses following the introduction
of the 2001 legislation on pack sizes there [6], although
the size of overdose for which calls were made to the
National Poisons Centre decreased in the first two years
after the legislation was introduced [12]. In England,
reductions were found in deaths and in liver transplants
due to paracetamol overdose following the 1998 UK leg-
islation [1,7].
Conclusions
This study has shown that people who take paracetamol
overdoses tend to consume numbers of tablets related
to available pack sizes. In Ireland, people tended more
often than in England to take numbers of tablets equiva-
lent to multiple packs. This raises the question of
whether this reflects differences in patients’ characteris-
tics, access to care, and greater ease of purchasing mul-
tiple packs in Ireland compared to England. The
findings suggest that smaller packs of paracetamol sold
through Irish pharmacy and non-pharmacy outlets may
be associated with smaller overdoses than in England in
females aged 35 years and over. However, no differences
were found in other age and gender groups. Currently,
data on death rates for paracetamol overdoses in Ireland
have not been published.
The findings do not provide information on whether a
further reduction in the maximum pack sizes for parace-
tamol sold over the counter in the UK would have
further beneficial effects on size of overdoses (and hence
on deaths from paracetamol overdose). Further investi-
gation of whether there are differences in enforcement
of legislatory advice on sales would be of interest, as
would further comparative studies of the apparent
effects of the legislation in the two countries on deaths
and hepatotoxicity.
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